Satavaptan
Template:Short description Template:Short description <templatestyles src="Infobox drug/styles.css"/> Script error: No such module "Infobox".Template:Template otherScript error: No such module "TemplatePar".{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = Satavaptan | INN = | _drugtype =
| _has_physiological_data= | _has_gene_therapy=
| vaccine_type= | mab_type= | _number_of_combo_chemicals=Script error: No such module "ParameterCount". | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=334538C1COCCN1CCO[C@H]2CC[C@](CC2)3c4cc(OCC)ccc4N(C3=O)S(=O)(=O)c5ccc(cc5OC)C(=O)NC(C)(C)C1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37)/t24-,33+QKXJWFOKVQWEDZ-VCCCEUOBSA-NTemplate:StdinchiciteTemplate:Stdinchicite | _combo_data= | _physiological_data= | _clinical_data= none | _legal_data=
| _other_data=N-(tert-butyl)-4-{[(1s,4s)-5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indol]-1'(2'H)-yl]sulfonyl}-3-methoxybenzamide
| _image_0_or_2 = Satavaptan structure.svg | _image_LR =
| _datapage = Satavaptan (data page) | _vaccine_target=_type_not_vaccine | _legal_all= | _ATC_prefix_supplemental=none | _has_EMA_link = | CAS_number=185913-78-4 | PubChem=9810773 | ChemSpiderID=32699105 | ChEBI= | ChEMBL= | DrugBank= | KEGG= | _hasInChI_or_Key=yes | UNII=AJS8S3P31H | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =
| _countSecondIDs=Script error: No such module "ParameterCount". | _countIndexlabels=Script error: No such module "ParameterCount". | _trackListSortletter= |QID = |QID2 = |Verifiedfields=changed |Watchedfields=changed |verifiedrevid=455169440}}
Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin V2 receptor antagonist[1] which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites.[2] Development was discontinued in 2009.[3]
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".